Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis

IVIG may be a helpful adjunctive therapy in the amelioration of some key clinical aspects in refractory SSc. Sustained benefit from IVIG suggests a specific immunomodulatory effect on those with established SSc GI complications.